Skip to main content

Table 1 Baseline characteristic of participants according to sex and stages of FPG changes (mmol/L)

From: Nonlinear association between changes in fasting plasma glucose and the incidence of diabetes in a nondiabetic Chinese cohort

 

Women

Men

Stage-1

< -0.24

Stage-2

-0.24—1.15

Stage-3

≥ 1.16

P-value

Stage-1

< -0.05

Stage-2

-0.05—1.31

Stage-3

≥ 1.32

P-value

N

12,076

39,132

2762

 

21,238

38,353

3255

 

Age (years)

43.40 ± 12.64

43.40 ± 12.39

48.96 ± 14.26

 < 0.001

44.10 ± 13.25

44.26 ± 13.06

48.38 ± 13.64

 < 0.001

Height (cm)

160.08 ± 5.64

160.11 ± 5.63

159.20 ± 5.98

 < 0.001

171.61 ± 6.26

171.68 ± 6.21

171.49 ± 6.41

0.162

Weight (kg)

56.97 ± 8.24

56.73 ± 8.09

58.50 ± 9.10

 < 0.001

71.67 ± 10.64

71.57 ± 10.49

74.41 ± 11.54

 < 0.001

BMI (kg/m2)

22.24 ± 3.08

22.13 ± 3.02

23.10 ± 3.51

 < 0.001

24.31 ± 3.17

24.26 ± 3.14

25.27 ± 3.45

 < 0.001

SBP (mmHg)

115.32 ± 16.37

114.80 ± 16.53

121.72 ± 20.26

 < 0.001

123.03 ± 15.60

122.70 ± 15.61

126.15 ± 17.71

 < 0.001

DBP (mmHg)

71.48 ± 10.32

71.30 ± 10.42

74.90 ± 11.62

 < 0.001

76.69 ± 10.61

76.83 ± 10.71

79.93 ± 11.70

 < 0.001

FPG (mmol/L)

5.29 ± 0.47

4.79 ± 0.51

4.42 ± 0.80

 < 0.001

5.34 ± 0.50

4.84 ± 0.57

4.62 ± 1.00

 < 0.001

TC (mmol/L)

4.81 ± 0.93

4.75 ± 0.91

4.89 ± 0.92

 < 0.001

4.84 ± 0.90

4.78 ± 0.87

4.86 ± 0.88

 < 0.001

TG (mmol/L)

1.12 ± 0.82

1.07 ± 0.72

1.28 ± 0.90

 < 0.001

1.65 ± 1.24

1.59 ± 1.13

1.84 ± 1.31

 < 0.001

HDL-C (mmol/L)

1.48 ± 0.31

1.47 ± 0.31

1.47 ± 0.31

0.011

1.29 ± 0.27

1.29 ± 0.28

1.24 ± 0.27

 < 0.001

LDL-C (mmol/L)

2.78 ± 0.70

2.73 ± 0.69

2.80 ± 0.67

 < 0.001

2.83 ± 0.69

2.77 ± 0.66

2.80 ± 0.65

 < 0.001

ALT (IU/L)

17.18 ± 13.82

17.17 ± 14.97

21.00 ± 42.88

 < 0.001

28.87 ± 21.55

29.27 ± 24.07

33.83 ± 30.97

 < 0.001

AST (IU/L)

21.84 ± 10.48

21.69 ± 9.01

24.44 ± 27.94

 < 0.001

25.61 ± 10.60

25.76 ± 13.81

28.39 ± 19.92

 < 0.001

BUN (mmol/L)

4.44 ± 1.15

4.37 ± 1.12

4.44 ± 1.18

 < 0.001

4.99 ± 1.18

4.91 ± 1.14

4.89 ± 1.16

 < 0.001

CCR (μmol/L)

57.82 ± 9.76

58.42 ± 10.51

59.10 ± 11.66

 < 0.001

80.43 ± 12.01

80.71 ± 11.97

79.47 ± 11.99

 < 0.001

FPG of final visit (mmol/L)

4.76 ± 0.43

5.10 ± 0.48

6.03 ± 1.22

 < 0.001

4.93 ± 0.48

5.31 ± 0.55

6.66 ± 1.82

 < 0.001

Family history of diabetes, N (%)

355 (2.94%)

1162 (2.97%)

92 (3.33%)

0.533

321 (1.51%)

627 (1.63%)

82 (2.52%)

 < 0.001

  1. Continuous variables are presented as the mean ± standard deviation (normal distribution); categorical variables are presented d as number (%). FPG changes was defined as the difference between the baseline and final visit FPG (FPG2) (mmol/L). ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; BUN, blood urea nitrogen; CCR, endogenous creatinine clearance rate; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; MBP, mean systolic blood pressure; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride. $ N (%) refers to the number and proportion of the identical sex group. # Diagnosis of incident diabetes was defined as fasting plasma glucose of ≥ 7.00 mmol/L and/or self-reported diabetes during the follow-up period. All trend for baseline characteristic of participants among age and groups, P < 0.001. In women: stage-1: < -0.24 mmol/L; stage-2: -0.24—1.15 mmol/L; stage-3: ≥ 1.16 mmol/L. In men: stage-1: < -0.05 mmol/L; stage-2: -0.05—1.31 mmol/L; stage-3: ≥ 1.32 mmol/L
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us